Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QPS, a full-service GLP/GCP-compliant contract research organisation (CRO) providing testing services to support preclinical and clinical research and development, has acquired Xendo Drug Development (XDD), headquartered in Groningen, The Netherlands.
Subscribe to our email newsletter
With the completion of this acquisition, QPS further expands its linearly integrated resources and services which consists of drug discovery and development from preclinical to clinical studies for IND and NDA regulatory submissions, start-up time for phase 1 clinical trials is four to six weeks, compared to several months in other European countries.
It also includes complete ADME package for regulatory submissions from preclinical studies to radiolabeled human mass balance (including microdosing) studies, CNS drug research and development.
XDD claimed that it has large and small molecule bioanalytical laboratories and a 24-bed clinical pharmacology unit (CPU) located at University Medical Center Groningen (UMCG) which was established in 2004.
Ben Chien, chairman, and CEO of QPS, said: “Our capability in conducting quality bioanalysis and Phase 1 studies, combined with our expertise in ADME, genotyping and drug development process is expected to make QPS an ideal drug development partner for our pharmaceutical and biotech clients.”